Username Password
S&P 500: 1,351.68 Change: +0.14%

AMYLIN PHARMACEUTICALS INC (AMLN)

Overview
Price 17.05
Price Change Today 0.00 (0.00%)
P&P rating Rating: 2
Zacks Rank 3 - HOLD
Open Price $0.00
Previous Close $17.05
Daily Range $0.00 - $0.00
52-Week Range $8.03 - $18.30
Volume 0
chart
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN injection and BYETTA injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over one thousand five hundred employees nationwide.
Other Resources for AMLN
zacks.com
Commentary
Zacks Blog: Novo Nordisk Posts Solid 4Q
February 6, 2012
Zacks Blog: The Zacks Analyst Blog Highlights: Alkermes plc, Elan, Johnson & Johnson, Amylin Pharmaceuticals and Eli Lilly & Company
February 6, 2012
Zacks Blog: Revenues Skyrocket at Merged Alkermes
February 3, 2012
Zacks Blog: New Study for Alkermes' Vivitrol
February 1, 2012
Zacks Blog: Zyprexa Pulls Down Lilly's 4Q Sales
January 31, 2012
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN injection and BYETTA injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over one thousand five hundred employees nationwide.
 
Brokerage Analyst Recommendations
15 Brokerage Firms Covering AMLN
 
   
Strong Buy
5
Buy
0
Hold
7
Sell
0
Strong Sell
3
Average Broker Recommendation (ABR): 2.69
 
AMLN Ratings:BUY  SELL  HOLD
AMLN Consensus Forecasts
Rate this Stock!
You haven't rated this stock yet!

What The Community Thinks

Total Players

33 Buy
1 Sell
 
Top Buy Analysis
BUY: AMLN Rating: 2
Company: AMYLIN PHARMACEUTICALS INC.
Points: -9.38
Start Price: $12.27
Start Date: 06/17/2009 8:04 PM
musaafir
musaafir
P&P Score: 98.43
Recs:
Looking for long term

Comments: 1 | Comment


Top Sell Analysis
SELL: AMLN Rating: 2
Company: AMYLIN PHARMACEUTICALS INC.
Points: -15.80
Start Price: $9.68
Start Date: 04/03/2009 2:40 AM
OnIslandTrader
OnIslandTrader
P&P Score: 0.28
Recs:
Sold off on heavy volume

Comments: 0 | Comment

Blog Posts
User User Score Date Title Comments Last Comment
Vet67to82
95.96 04/08/11 Seagate Tech (STX) FairValue 2 01/21/12
Vet67to82
95.96 02/22/11 To buy or not to buy? That is the question. 1 02/22/11
rjm77me
99.92 02/09/11 What is better for your Real Money account? 30% in stock which was hit or 15% in Great Stock 8 02/11/11
Vet67to82
95.96 01/28/11 Friday January 28, 2011 - When Opportunity Knocks 0
Vet67to82
95.96 11/11/10 Thursday, 11/11/2010 OurCall for the Close 9 11/11/10
Vet67to82
95.96 11/10/10 Wednesday, 11/10/2010 OurCall for the Close 15 11/10/10
Vet67to82
95.96 11/09/10 Tuesday, 11/9/2010 OurCall for the Close 8 11/09/10
Vet67to82
95.96 11/07/10 Monday, 11/8/2010 OurCall for the Close 18 11/09/10
Vet67to82
95.96 11/05/10 Friday, 11/5/2010 OurCall for the Close 8 11/05/10
Vet67to82
95.96 11/04/10 Thursday, 11/4/2010 OurCall for the Close 9 11/04/10
Pages: [ 1 ]  2   3   4   5   ...  12  >>
Commentary
BUY: AMYLIN PHARMACEUTICALS INC. (AMLN) Rating: 2
Start Price: $19.96
Points: -34.59
Created: 08/05/2010
Once/week dosing of the currently selling and highly effective BID diabetes drug Exenatide (Byetta) is awaiting 22 Oct 2010 PDUFA date. Only question mark is the ability of management to market the drug. Management has displayed extreme ineptness in the past. Carl Icahn is a major holder.

Comments: 0 | Comment

Recs:
 
BUY: AMYLIN PHARMACEUTICALS INC. (AMLN) Rating: 2
Start Price: $18.50
Points: -34.16
Created: 07/21/2010
When FDA approves BYDUREON the stock will return to 50+

Comments: 0 | Comment

Recs:
 
BUY: AMYLIN PHARMACEUTICALS INC. (AMLN) Rating: 2
Start Price: $12.27
Points: -9.38
Created: 06/17/2009
Looking for long term

Comments: 1 | Comment

Recs:
 
BUY: AMYLIN PHARMACEUTICALS INC. (AMLN) Rating: 2
Start Price: $10.99
Points: -5.01
Created: 04/22/2009
looks good

Comments: 0 | Comment

Recs:
 
SELL: AMYLIN PHARMACEUTICALS INC. (AMLN) Rating: 2
Start Price: $9.68
Points: -15.80
Created: 04/03/2009
Sold off on heavy volume

Comments: 0 | Comment

Recs:
 
BUY: AMYLIN PHARMACEUTICALS INC. (AMLN) Rating: 2
Start Price: $6.14
Points: +110.27
Created: 11/19/2008
earnings

Comments: 0 | Comment

Recs:
 
BUY: AMYLIN PHARMACEUTICALS INC. (AMLN) Rating: 2
Start Price: $8.75
Points: +45.59
Created: 11/06/2008
Has a long acting version of their Byetta drug in testing stage for the treatment of diabetes. Will require injection once a week instead of 720 times a year. Should hit market within the next 3 years. Stock down from 50 to 8. Good long term speculation.

Comments: 0 | Comment

Recs:
 
BUY: AMYLIN PHARMACEUTICALS INC. (AMLN) Rating: 2
Start Price: $8.97
Points: +48.32
Created: 11/05/2008

Comments: 0 | Comment

Recs:
 
BUY: AMYLIN PHARMACEUTICALS INC. (AMLN) Rating: 2
Start Price: $11.34
Points: -0.29
Created: 10/22/2008

Comments: 0 | Comment

Recs:
 
BUY: AMYLIN PHARMACEUTICALS INC. (AMLN) Rating: 2
Start Price: $13.32
Points: -9.09
Created: 10/20/2008

Comments: 0 | Comment

Recs:
 
Pages: [ 1 ]  2   3   4  >>
Picks
Username P&P Score Call Time Frame Start Date Start Price Today (change) Stock Gain S&P Gain Points Analysis
BoscoSantini 3.60 BUY Three to Six Months 08/05/2010 $19.96 $17.06
(+3.14%)
-14.53% +20.06% -34.59 view
EOLSON80 BUY Three to Six Months 07/21/2010 $18.50 $17.06
(+3.14%)
-7.78% +26.37% -34.16 view
musaafir 98.43 BUY One to Three Months 06/17/2009 $12.27 $17.06
(+3.14%)
+39.04% +48.42% -9.38 view
oc759 10.34 BUY Six Months to a Year 04/22/2009 $10.99 $17.06
(+3.14%)
+55.23% +60.24% -5.01 view
OnIslandTrader 0.28 SELL One to Three Months 04/03/2009 $9.68 $17.06
(+3.14%)
+76.24% +60.44% -15.80 view
jolof65 31.66 BUY Six Months to a Year 11/19/2008 $6.14 $17.06
(+3.14%)
+177.85% +67.58% +110.27 view
geirs2 95.61 BUY One to Three Years 11/06/2008 $8.75 $17.06
(+3.14%)
+94.97% +49.38% +45.59 view
McFly 3.53 BUY Six Months to a Year 11/05/2008 $8.97 $17.06
(+3.14%)
+90.19% +41.87% +48.32
VivaLaBam 84.88 BUY Three Plus Years 10/22/2008 $11.34 $17.06
(+3.14%)
+50.44% +50.73% -0.29
Revolver 73.61 BUY Six Months to a Year 10/20/2008 $13.32 $17.06
(+3.14%)
+28.08% +37.17% -9.09
Pages: [ 1 ]  2   3   4  >>
Sponsored Links